(S (NP (NP (JJ High) (NN affinity) (NN aldosterone)) (VP (VBG binding) (PP (TO to) (NP (NP (NN plasma) (NN membrane) (JJ rich) (NNS fractions)) (PP (IN from) (NP (JJ mononuclear) (NNS leukocytes))))))) (: :) (SQ (VBZ is) (NP-SBJ (EX there)) (NP-PRD (NP (DT a) (NN membrane) (NN receptor)) (PP (IN for) (NP (NNS mineralocorticoids)))) (. ?)))
(S (NP-SBJ-COOD-56 (NP (NP (ADJP (FW In) (FW vitro)) (NNS effects)) (PP (IN of) (NP (NN aldosterone))) (PP (IN on) (NP (NP (DT the) (JJ intracellular) (NNS concentrations)) (PP (IN of) (NP-COOD (NP (NN sodium)) (, ,) (NP (NN potassium)) (CC and) (NP (NN calcium))))))) (, ,) (NP (NN cell) (NN volume)) (CC and) (NP (DT the) (NN sodium-proton-antiport))) (VP (VBP have) (VP (VBN been) (VP (VBN described) (NP (-NONE- *-56)) (PP (IN in) (NP (JJ intact) (NP (NP (JJ human) (JJ mononuclear) (NNS leukocytes)) (PRN (-LRB- -LRB-) (NP (NN HML)) (-RRB- -RRB-)))))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ present) (NN paper))) (, ,) (NP-SBJ-57 (NP (DT the) (NN binding)) (PP (IN of) (NP (DT a) (JJ -LCB-125I-RCB--labeled) (NN aldosterone) (JJ derivative))) (PP (TO to) (NP (NP (ADJP (NP (NN plasma) (NN membrane)) (JJ rich)) (NNS fractions)) (PP (IN of) (NP (NN HML)))))) (VP (VBD was) (VP (VBN studied) (NP (-NONE- *-57)))) (. .))
(S (NP-SBJ-58 (NP (JJ High) (NN affinity) (NN binding)) (PP (IN of) (NP (DT the) (NN radioligand))) (PP (IN with) (NP (NP (DT an) (JJ apparent) (NN Kd)) (PP (IN of) (NP (QP (RB approximately) (CD 0.1)) (NN nM)))))) (VP (VBD was) (VP (VBN found) (NP (-NONE- *-58)))) (. .))
(S (NP-SBJ (NN Aldosterone)) (VP (VBD displaced) (NP (DT the) (NN tracer)) (PP (IN at) (NP (DT a) (JJ similar) (NN Kd)))) (. .))
(S (NP-SBJ-COOD (CC Both) (NP (NN canrenone)) (CC and) (NP (NN cortisol))) (VP (VBD were) (ADJP-PRD (JJ inactive)) (PP (IN as) (NP (NNS ligands))) (PP (RB up) (TO to) (NP (NP (NNS concentrations)) (PP (IN of) (NP (CD 0.1) (NN microM)))))) (. .))
(S (NP-SBJ (DT The) (NNS findings)) (VP (VBP are) (NP-PRD (NP (DT the) (JJ first)) (SBAR (WHNP-305 (-NONE- 0)) (S (NP-SBJ (-NONE- *T*-305)) (VP (TO to) (VP (VB demonstrate) (NP (NP (NN membrane) (NN binding) (NNS sites)) (PP (IN with) (NP (DT a) (JJ high) (NN affinity))) (PP-COOD (PP (IN for) (NP (NN aldosterone))) (, ,) (CC but) (PP (RB not) (IN for) (NP (NN cortisol))))))))))) (. .))
(S (NP-SBJ (DT These) (NNS data)) (VP-COOD (VP (VBP are) (ADJP-PRD (RB perfectly) (JJ compatible) (PP (IN with) (NP (NP (JJ major) (NNS properties)) (PP (IN of) (NP (NP (JJ steroidal) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN sodium-proton-antiport)) (PP (IN in) (NP (NN HML))))))))))) (CC and) (RB thus) (VP (ADVP (RB very) (RB likely)) (VBP represent) (NP (NP (NN membrane) (NNS receptors)) (PP (IN for) (NP (NN aldosterone)))))) (. .))
